1st approved Symbicort generic, Breyna, now available in US
Aug 7, 2023 · The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available to eligible patients.. Like Symbicort, Breyna is approved as a maintenance therapy to lower airflow obstruction and prevent exacerbations in people with COPD, and for asthma patients, ages 6 and older.
Low-dose Morphine Improves Health in COPD Patients With …
Sep 3, 2020 · So, researchers based at the Maastricht University in the Netherlands designed the Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) Phase 4 study (NCT02429050).It investigated whether regular, low-dose, oral sustained-release morphine improved health in COPD patients with moderate-to-very-severe chronic breathlessness.
Ohtuvayre effective across key patient subgroups: ENHANCE trials
Oct 14, 2024 · In an oral presentation titled “Ensifentrine Improved Lung Function, Symptoms, and Quality of Life Regardless of COPD Severity,” Jessica M. Bon, MD, of Wake Forest University School of Medicine, shared Ohtuvarye’s effects in subgroups of ENHANCE participants stratified by COPD severity. The results showed that Ohtuvaryre led to significant improvements in lung function after three months ...
A form of vitamin B3 lowers COPD lung inflammation: Study
Nov 25, 2024 · Assessing inflammation with vitamin B supplement. The University of Copenhagen launched a single-center trial (NCT04990869) at the Respiratory Research Unit at Bispebjerg Hospital in Copenhagen to test nicotinamide riboside against a placebo for its potential as a COPD treatment. The study included 40 adults, mean age 71.9, who had COPD, a history of heavy smoking, and low numbers of ...
LupinHaler, generic version of Spiriva HandiHaler, available in US
Aug 28, 2023 · In Europe, generics of Boehringer Ingelheim’s Spiriva HandiHaler began launching in 2021, including ones from Glenmark Pharmaceuticals and Phargentis, but these medications haven’t become available in the U.S.. COPD is a chronic lung disease wherein the airways become blocked, leading to progressively worsening disease symptoms that include shortness of breath and wheezing.
Dupixent approved in US for adults with poorly controlled COPD
Sep 30, 2024 · In the U.S., the expansion of Dupixent’s label to include COPD brings the number of approved indications up to six, adding to its use as a treatment for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis — all driven in part by type 2 inflammation. “Dupixent has already shown it can revolutionize the treatment paradigm ...
Ensifentrine, now Ohtuvayre, wins FDA approval for COPD
Jun 27, 2024 · Verona did not specify the list price for the newly approved therapy. According to an analysis from the Institute for Clinical Economic Review (ICER), Ohtuvayre would meet common cost-effectiveness thresholds if its annual price is between $7,500 and $12,700. ICER is a nonprofit organization whose therapy cost-effectiveness assessments increasingly influence price negotiations and ...
My worsening COPD symptoms have prompted a change of habits
Oct 30, 2024 · Just how long can a person have low oxygen saturation before damage occurs? The answer is unknown. I feel that any amount of time with low oxygen saturation is too long, as expressed in a 2019 COPD News Today article, “Oxygen Manifesto, Part 1: Advice from 3 Respiratory Therapists.”. I’m not sure my oxygen saturation is staying above 88% while using my portable concentrator because I don ...
DirectRx pharmacy distributing COPD therapy Ohtuvayre in US
Sep 9, 2024 · The Verona Pharma therapy, with a list price of $2,950 for a monthly supply, was cleared by the U.S. Food and Drug Administration in June as an inhaled maintenance therapy for adults with COPD. “We followed the clinical trials closely which found that Ohtuvayre demonstrated both early and sustained improvements in lung function across a broad population of patients with COPD,” Amanda ...
Urine test may predict COPD exacerbations days in advance: Study
Dec 9, 2024 · Developing a test like ‘a personal weather forecast of an impending flare-up’ COPD occurs when long-lasting inflammation damages the airways, causing symptoms such as shortness of breath, persistent cough, and recurrent infections. Exacerbations, or flare-ups, are the “principal driver of poor health status, [hospitalizations], mortality and healthcare costs,” the researchers wrote.